Current Edition

checkpoint inhibitors

Merck, Eisai’s 007 goes down as Keytruda-Lenvima combo fails in newly diagnosed lung cancer

Merck & Co. isn’t resting on Keytruda’s laurels. But an attempt to improve on the undoubtful cancer immunotherapy king with another agent has failed in …

Continue Reading →
Acceleron

Merck’s reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom

Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond …

Continue Reading →
Belzutifan

Merck’s Welireg scores FDA nod in cancers spurred by rare disease—and its label is broader than expected

Merck’s $1.1 billion bet on Peloton Therapeutics is starting to pay off. Belzutifan, one of the most lucrative assets Merck picked up through its 2019 …

Continue Reading →
breast cancer

Merck’s Keytruda scores first-in-class nod in early triple-negative breast cancer despite FDA’s prior reluctance

The FDA had reservations about Merck & Co.’s proposed use of Keytruda around surgery for patients with early triple-negative breast cancer. But less than three …

Continue Reading →